Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.

Saved in:
Bibliographic Details
Title: Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.
Authors: Olawaiye AB; University of Pittsburgh School of Medicine and UPMC Magee-Women's Hospital, Gynecologic Oncology Group, Pittsburgh, PA, USA. Electronic address: olawaiyea@upmc.edu., Gladieff L; Oncopole Claudius Regaud IUCT-Oncopole, Toulouse, France; GINECO, Paris, France., O'Malley DM; James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA., Kim JW; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, South Korea., Garbaos G; Instituto Médico de la Fundación Estudios Clínicos, Santa Fe, Argentina., Salutari V; Department of Woman, Child, and Public Health, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy., Gilbert L; Division of Gynecologic Oncology, Research Institute, McGill University Health Centre, Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada., Mileshkin L; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Devaux A; Oncology Department of Grand Hôpital de Charleroi, Charleroi, Belgium; Belgium and Luxembourg Gynaecological Oncology Group, Leuven, Belgium., Hopp E; Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, USA., Lee YJ; Yonsei University College of Medicine, Seoul, South Korea., Oaknin A; Medical Oncology Service, Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Scaranti M; DASA Oncologia, Hospital 9 de Julho, São Paulo, Brazil., Kim BG; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Colombo N; Gynecologic Oncology Program, European Institute of Oncology, IRCCS, Milan, Italy; Department of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy., McCollum ME; Virginia Oncology Associates, Norfolk, VA, USA., Diakos C; Royal North Shore Hospital, St Leonards, NSW, Australia., Clamp A; The Christie NHS Foundation Trust, Manchester, UK; University of Manchester, Manchester, UK., Leiser AL; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Balázs B; Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary., Monk BJ; Florida Cancer Specialists and Research Institute, West Palm Beach, FL, USA., Scandurra G; Medical Oncology Unit, Cannizzaro Hospital, Catania, Italy; Faculty of Medicine, Kore University of Enna, Enna, Italy., McClung E; Stanford University, Palo Alto, CA, USA., Kaczmarek E; Centre Oscar Lambret, Lille, France; GINECO, Paris, France., Slomovitz B; Mount Sinai Comprehensive Cancer Center, Miami Beach, FL, USA., De La Cueva H; Hospital La Fe Valencia, Valencia, Spain., de Carvalho Calabrich AF; Ensino e Terapia de Inovação Clínica AMO-ETICA, Salvador, Brazil., Cassani C; Department of Clinical, Surgical, Diagnostic, and Pediatric Sciences, University of Pavia, Pavia, Italy; Unit of Obstetrics and Gynecology, IRCCS San Matteo Foundation, Pavia, Italy., You B; GINECO, Paris, France; Lyon University Hospital (HCL), Lyon, France., Van Gorp T; University Hospital Leuven, Leuven Cancer Institute, Leuven, Belgium; Belgium and Luxembourg Gynaecological Oncology Group, Leuven, Belgium., Churruca C; Hospital Donostia, San Sebastián, Spain., Caruso G; Gynecologic Oncology Program, European Institute of Oncology, IRCCS, Milan, Italy; Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy., Nicum S; University College Hospital, London, UK., Bagaméri A; Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary., Artioli G; Azienda ULSS2 Marca Trevigiana, Treviso, Italy., Bodnar L; Institute of Health Sciences, University of Siedlce, Siedlce, Poland., Kang S; Department of Cancer Control and Population Health, National Cancer Center, Goyang, South Korea., Vergote I; Department of Gynecologic Oncology, University Hospital Leuven, Leuven, Belgium., Kesner-Hays A; Corcept Therapeutics, Redwood City, CA, USA., Pashova HI; Corcept Therapeutics, Redwood City, CA, USA., Pai SG; Corcept Therapeutics, Redwood City, CA, USA., Tudor IC; Corcept Therapeutics, Redwood City, CA, USA., Jubb AM; Corcept Therapeutics, Redwood City, CA, USA., Lorusso D; Department of Biomedical Science, Humanitas University, Pieve Emanuele, Italy; Humanitas San Pio X Hospital, Milan, Italy.
Source: Lancet (London, England) [Lancet] 2025 Jun 21; Vol. 405 (10496), pp. 2205-2216. Date of Electronic Publication: 2025 Jun 02.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-547X
DOI:10.1016/S0140-6736(25)01040-2